Data from the National Institute on Drug Abuse shows that millions of individuals in America have already battled or will battle addiction to drugs, with 85% of them relapsing within one year of treatment. A recently launched program is hoping to lower this number significantly. The program, which was launched in Austin, Texas, will be administering ketamine therapy to eligible patients.
The center, which has been christened Within, plans to combine psychedelic medicine with functional wellness and holistic healing in the treatment of addictions and mental disorders, including depression, post-traumatic stress disorder and substance abuse. Ryan Saldanha, a resident of Austin, revealed that he’d undergone ketamine therapy after relapsing for a number of years. He explained that receiving psychedelic therapy gave him hope.
Luke Carver, who was also addicted to a number of substances before he tried psychedelic therapy, shared his story too. Carver stated that the administration of psychedelic therapy such as ketamine made the brain’s neuroplasticity increase significantly, which gave patients a chance to reprogram their brains and develop new patterns and habits in their lives.
Within medical director Eric Miller stated that he’d watched individuals go in and out of the hospital for years, being prescribed more medications, yet their conditions did not improve. He noted that psychedelic therapy prompted a shift from coping to healing.
Jennifer Zuckerman, a nurse practitioner who recently relocated to California to help with the program’s launch, echoed what Miller stated. She revealed that having worked in private practice for years, she had observed that people were prescribed more and more drugs in the course of their treatments. Zuckerman noted that despite the presence of a lot of tools and teachings from modern medicine, a lot more improvement ad support was needed, particularly when it came to mental health.
In the recent past, we’ve seen interest in the use of psychedelic therapy increase significantly, catching the attention of legislators, researchers and medical professionals alike. Toward the end of 2021, the Dell Medical School at the University of Texas at Austin launched the Center for Psychedelic Research and Therapy. The center’s objective is to look into the use of psychedelic drugs as treatments for a range of mental health conditions.
Additionally, Harvard Law School launched the Project on Psychedelics Law and Regulation under the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics. This project’s objective is to examine the social, legal and ethical implications of psychedelic therapeutics, commerce and research.
Given that a lot of psychedelic drug development is being undertaken by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), the involvement of academia in shaping the direction of the industry will result in greater benefits for society in general since each party will play its part in the growth of the sector.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…